Latest Period
Q1 2026
Security Snapshot
Telix Pharmaceuticals Ltd - Ordinary Shares (TLX) Institutional Ownership
CUSIP: 87961M105
13F Institutional Holders and Ownership History from Q4 2024 to Q1 2026
Institutions Reporting
37
Shares (Excl. Options)
2,569,571
Price
$9.57
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary Shares
- Symbol
- TLX on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 2,569,571
- Total 13F value
- $24,476,081
- Portfolio coverage rank
- 0%
- Share change
- +1,439,063
- Value change
- +$14,117,996
- Number of holders
- 37
- Shares outstanding
- 334,705,968
- SEC-reported price per share
- $9.53
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- TLX - Telix Pharmaceuticals Ltd - Ordinary Shares is tracked under CUSIP 87961M105.
- 37 institutions reported positions in Q1 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 39 to 37 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $8,466,233 to $24,476,081.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 37 institutions filings for Q1 2026.
Security key
87961M105
Latest holder period
Q1 2026
13F holders
37
13D/G owners
2
CIK / CUSIP context first
Open Q1 2026 holders
TLX full holder history
Telix Pharmaceuticals Ltd SEC filings
Telix Pharmaceuticals Ltd company facts
Telix Pharmaceuticals Ltd insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 87961M105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
TLX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Behrenbruch Christian | 7% | $404,991,544 | 23,329,006 | Behrenbruch Christian | 12 Nov 2024 | |||
| Kluge Andreas | 6.8% | $393,638,000 | 22,675,000 | Kluge Andreas | 12 Nov 2024 |
As of 31 Mar 2026, 37 institutional investors reported holding 2,569,571 shares of Telix Pharmaceuticals Ltd - Ordinary Shares (TLX). This represents 0.77% of the company’s total 334,705,968 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
6
Latest
Q1 2026
Rows shown
1-6 of 6
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 2,569,571 | $24,476,081 | +$14,117,996 | $9.57 | 37 |
| 2025 Q4 | 1,121,093 | $8,466,233 | +$2,229,104 | $7.49 | 39 |
| 2025 Q3 | 823,173 | $7,877,366 | +$1,551,679 | $9.57 | 27 |
| 2025 Q2 | 452,466 | $7,285,409 | +$6,501,020 | $16.07 | 21 |
| 2025 Q1 | 47,647 | $798,562 | +$736,047 | $16.76 | 6 |
| 2024 Q4 | 3,730 | $57,442 | +$57,442 | $15.40 | 1 |